Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
h31G2m2A9B10UHPQ
